FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136405361> ?p ?o ?g. }

• W3136405361 abstract "Objectives Astragaloside IV (AS-IV), the main active component of Astragalus membranaceus, bears anti-inflammatory, antioxidant, and neuroprotective activity. Parkinson’s disease (PD) is a common neurodegenerative disease. This study explored the protective effect of AS-IV on the cell model of PD. Materials and Methods SH-SY5Y cells were incubated with different concentrations (10, 50, 100, 150, and 200 μM) of 6-hydroxydopamine (6-OHDA) for 0, 3, 6, 12, 24, and 48 h to establish the PD cell model. Different concentrations (0, 25, 50, 100, 150, and 200 μM) of AS-IV or 15 mM JAK2/STAT3 pathway inhibitor SC99 was added for intervention 2 h before 6-OHDA treatment. The viability and morphological damage of 6-OHDA-treated SH-SY5Y cells were measured using MTT assay and Hoechst 33258 staining. The expression of microtubule associated protein 2 (MAP2) was detected by immunofluorescence staining. The levels of inflammation and oxidative stress were measured using ELISA. Apoptosis of 6-OHDA-treated SH-SY5Y cells was detected using flow cytometry, and phosphorylation level of JAK2 and STAT3 were detected using Western blot analysis. Results The survival rate of SH-SY5Y cells treated with 100 μM 6-OHDA for 24 h was about 50%. AS-IV (25–100 μM) significantly improved the viability (all p &lt; 0.01), increased MAP2 expression, and repaired the morphological damage induced by 6-OHDA. AS-IV inhibited IL-1β, IL-6, and TNF-α level (all p &lt; 0.05), reduced MDA and ROS content and increased SOD concentration, thereby reducing inflammation and oxidative stress (all p &lt; 0.01) in 6-OHDA-treated SH-SY5Y cells. Moreover, AS-IV decreased apoptosis rate and Bax/Bcl-2 ratio induced by 6-OHDA (all p &lt; 0.05). Mechanically, AS-IV significantly increased the phosphorylation of JAK2 and STAT3 ( p &lt; 0.01); the addition of SC99 decreased the cell viability, increased the apoptosis rate, enhanced the levels of inflammatory factors and oxidative stress. Conclusion AS-IV enhanced the cell viability, and inhibited apoptosis, inflammation and oxidative stress of 6-OHDA-treated SH-SY5Y cells via activating the JAK2/STAT3 signaling pathway. This study may confer novel insights for the management of PD." @default.
• W3136405361 created "2021-03-29" @default.
• W3136405361 creator A5014589918 @default.
• W3136405361 creator A5038125200 @default.
• W3136405361 creator A5052413979 @default.
• W3136405361 creator A5061188952 @default.
• W3136405361 date "2021-03-23" @default.
• W3136405361 modified "2023-10-16" @default.
• W3136405361 title "Astragaloside IV Protects 6-Hydroxydopamine-Induced SH-SY5Y Cell Model of Parkinson’s Disease via Activating the JAK2/STAT3 Pathway" @default.
• W3136405361 cites W1980644890 @default.
• W3136405361 cites W2022545956 @default.
• W3136405361 cites W2028319159 @default.
• W3136405361 cites W2044542314 @default.
• W3136405361 cites W2044951529 @default.
• W3136405361 cites W2093120223 @default.
• W3136405361 cites W2093397833 @default.
• W3136405361 cites W2107632774 @default.
• W3136405361 cites W2288152950 @default.
• W3136405361 cites W2291597794 @default.
• W3136405361 cites W2420111953 @default.
• W3136405361 cites W2460047345 @default.
• W3136405361 cites W2525903933 @default.
• W3136405361 cites W2531872507 @default.
• W3136405361 cites W2535730691 @default.
• W3136405361 cites W2548036684 @default.
• W3136405361 cites W2581824660 @default.
• W3136405361 cites W2601663967 @default.
• W3136405361 cites W2732003302 @default.
• W3136405361 cites W2748162767 @default.
• W3136405361 cites W2759219831 @default.
• W3136405361 cites W2759710830 @default.
• W3136405361 cites W2767241172 @default.
• W3136405361 cites W2791695830 @default.
• W3136405361 cites W2807536020 @default.
• W3136405361 cites W2890007492 @default.
• W3136405361 cites W2953625438 @default.
• W3136405361 cites W2967391877 @default.
• W3136405361 cites W2967769978 @default.
• W3136405361 cites W2995251130 @default.
• W3136405361 cites W2995639486 @default.
• W3136405361 cites W2995653856 @default.
• W3136405361 cites W3004704115 @default.
• W3136405361 cites W3005720713 @default.
• W3136405361 cites W3007905534 @default.
• W3136405361 cites W3014221457 @default.
• W3136405361 cites W3020397684 @default.
• W3136405361 cites W3033254163 @default.
• W3136405361 cites W3036286531 @default.
• W3136405361 cites W3040739694 @default.
• W3136405361 cites W3042725802 @default.
• W3136405361 cites W3043336775 @default.
• W3136405361 doi "https://doi.org/10.3389/fnins.2021.631501" @default.
• W3136405361 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8021720" @default.
• W3136405361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33833662" @default.
• W3136405361 hasPublicationYear "2021" @default.
• W3136405361 type Work @default.
• W3136405361 sameAs 3136405361 @default.
• W3136405361 citedByCount "17" @default.
• W3136405361 countsByYear W31364053612021 @default.
• W3136405361 countsByYear W31364053612022 @default.
• W3136405361 countsByYear W31364053612023 @default.
• W3136405361 crossrefType "journal-article" @default.
• W3136405361 hasAuthorship W3136405361A5014589918 @default.
• W3136405361 hasAuthorship W3136405361A5038125200 @default.
• W3136405361 hasAuthorship W3136405361A5052413979 @default.
• W3136405361 hasAuthorship W3136405361A5061188952 @default.
• W3136405361 hasBestOaLocation W31364053611 @default.
• W3136405361 hasConcept C104317684 @default.
• W3136405361 hasConcept C126322002 @default.
• W3136405361 hasConcept C153911025 @default.
• W3136405361 hasConcept C185592680 @default.
• W3136405361 hasConcept C190283241 @default.
• W3136405361 hasConcept C25498285 @default.
• W3136405361 hasConcept C2776151105 @default.
• W3136405361 hasConcept C2776415932 @default.
• W3136405361 hasConcept C2776715637 @default.
• W3136405361 hasConcept C2779083432 @default.
• W3136405361 hasConcept C2779134260 @default.
• W3136405361 hasConcept C2779734285 @default.
• W3136405361 hasConcept C2780783641 @default.
• W3136405361 hasConcept C2911016594 @default.
• W3136405361 hasConcept C53227056 @default.
• W3136405361 hasConcept C54355233 @default.
• W3136405361 hasConcept C553184892 @default.
• W3136405361 hasConcept C55493867 @default.
• W3136405361 hasConcept C71924100 @default.
• W3136405361 hasConcept C81885089 @default.
• W3136405361 hasConcept C86803240 @default.
• W3136405361 hasConcept C98274493 @default.
• W3136405361 hasConceptScore W3136405361C104317684 @default.
• W3136405361 hasConceptScore W3136405361C126322002 @default.
• W3136405361 hasConceptScore W3136405361C153911025 @default.
• W3136405361 hasConceptScore W3136405361C185592680 @default.
• W3136405361 hasConceptScore W3136405361C190283241 @default.
• W3136405361 hasConceptScore W3136405361C25498285 @default.
• W3136405361 hasConceptScore W3136405361C2776151105 @default.
• W3136405361 hasConceptScore W3136405361C2776415932 @default.
• W3136405361 hasConceptScore W3136405361C2776715637 @default.
• W3136405361 hasConceptScore W3136405361C2779083432 @default.
• W3136405361 hasConceptScore W3136405361C2779134260 @default.

• next